Radisens and Beckman Coulter sign Collaborative Development and Evaluation Agreement
Cork, Ireland – May 29, 2012 – Radisens Diagnostics and Beckman Coulter, Inc. have announced that they have entered into a Collaborative Development and Evaluation Agreement to exploit Radisens Diagnostics’ proprietary platform technology for cellular analysis applications.
Comprising part of Radisens point-of-care diagnostic platform, the proprietary digital HDR™ detection engine delivers industry leading multi-colour fluorescence and scattering sensitivity. This matchbox-sized HDR™ detection engine delivers a step-change in the market for portable multi-fluorescent flow cytometers, cell analysers and diagnostic devices. The six decades of optical dynamic range enables truly automatic sample-to-answer operation, with the digital solid-state technology removing the need for expensive maintenance cycles, while significantly reducing instrument cost.
Jerry O’Brien, CEO of Radisens Diagnostics said, “This strategic collaboration with Beckman Coulter demonstrates the disruptive nature of the diagnostics technology that we are developing at Radisens in terms of performance, cost and usability. This opens up huge growth opportunities in providing clinicians and researchers a powerful, low-cost diagnostic tool onto their desk with the advanced laboratory performance they require.”
Commenting on the deal, Mario Koksch, Director Product Management for Flow Cytometry at Beckman Coulter, Inc., said “We are very excited by the potential performance, cost and usability benefits that Radisens can bring with its proprietary HDR™ detection technology. We look forward to realizing the huge potential this offers within emerging high-growth flow cytometry markets, while maintaining a reputation for high performance.”
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland.
About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, CA, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 275,000 Beckman Coulter systems operate in both diagnostics and life sciences laboratories on six continents. For more than 75 years, Beckman Coulter products have been making a difference in peoples’ lives by improving the productivity of medical professionals and scientists, supplying critical information for improving patient health and reducing the cost of care. For more information, visit www.beckmancoulter.com.
Radisens Diagnostics Ltd.
E: info (at) radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909